ObjectiveTo analyze the influencing factors of acute exacerbation readmission in elderly patients with chronic obstructive pulmonary disease (COPD) within 30 days, construct and validate the risk prediction model.MethodsA total of 1120 elderly patients with COPD in the respiratory department of 13 general hospitals in Ningxia from April 2019 to August 2020 were selected by convenience sampling method and followed up until 30 days after discharge. According to the time of filling in the questionnaire, 784 patients who entered the study first served as the modeling group, and 336 patients who entered the study later served as the validation group to verify the prediction effect of the model.ResultsEducation level, smoking status, number of acute exacerbations of COPD hospitalizations in the past 1 year, regular use of medication, rehabilitation and exercise, nutritional status and seasonal factors were the influencing factors of patients’ readmission to hospital. The risk prediction model was constructed: Z=–8.225–0.310×assignment of education level+0.564×assignment of smoking status+0.873×assignment of number of acute exacerbations of COPD hospitalizations in the past 1 year+0.779×assignment of regular use of medication+0.617×assignment of rehabilitation and exercise +0.970×assignment of nutritional status+assignment of seasonal factors [1.170×spring (0, 1)+0.793×autumn (0, 1)+1.488×winter (0, 1)]. The area under ROC curve was 0.746, the sensitivity was 75.90%, and the specificity was 64.30%. Hosmer-Lemeshow test showed that P=0.278. Results of model validation showed that the sensitivity, the specificity and the accuracy were 69.44%, 85.71% and 81.56%, respectively.ConclusionsEducation level, smoking status, number of acute exacerbations of COPD hospitalizations in the past 1 year, regular use of medication, rehabilitation and exercise, nutritional status and seasonal factors are the influencing factors of patients’ readmission to hospital. The risk prediction model is constructed based on these factor. This model has good prediction effect, can provide reference for the medical staff to take preventive treatment and nursing measures for high-risk patients.
ObjectiveTo explore the clinical phenotype of patients with acute exacerbation of chronic obstructive pulmonary disease (COPD) by cluster analysis and provide a basis for individualized treatment.MethodsA total of 515 patients with acute exacerbation of COPD admitted to this department from January 2014 to December 2016 were enrolled. The age, duration, smoking index, number of hospitalizations in the past 1 year, hospitalization days, treatment costs and other information were collected for cluster analysis.ResultsThe patients were divided into three categories of phenotype: " mild-glucocorticoid resistance-antibiotic dependent”," mild-glucocorticoid sensitive”, and " serious complication”. The patients with the first two phenotypes had a milder condition and lower hospitalization costs. There were differences in the time and cumulative dose of glucocorticoids in different pathways, antibiotic use time and usage rate. The third phenotype was the most serious, with the highest cost of hospitalization, and may merge or co-exist with other diseases such as cardiovascular disease and digestive tract disease.ConclusionCluster analysis may identify different phenotypes of acute exacerbation of COPD to provide a reference for clinical individualized treatment.
ObjectiveTo analyze the features and clinical significance of blood eosinophils (EOS) in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD).MethodsThe general data, laboratory examination and treatment of patients with AECOPD admitted to this department from January 2014 to December 2016 were analyzed retrospectively. Based on the inclusion of treatment targets for blood EOS according to 2018GOLD, patients were divided into group A (EOS<100 cells/μL), group B (100 cells/μL≤EOS≤300 cells/μL), and group C (EOS>300 cells/μL) with two cut-off levels. The differences in general data, severity, and glucocorticoid use between group A, group B and group C were compared.ResultsA total of 515 patients with AECOPD were enrolled. 10.87% of patients had blood EOS>300 cells/μL, and 39.03% of patients had blood EOS≥100 cells/μL. Patients in group B and C were younger, with shorter disease duration, intensive care unit stay time, non-invasive mechanical ventilation use time. The time of glucocorticoid administration was significantly shortened, and the cumulative dose of venous glucocorticoid, hospitalization cost, and total drug cost were also lower than those of group A (all P<0.05).ConclusionsPatients in group B and C are younger, shorter in disease duration, lower in severity and more responsive to glucocorticoid therapy. Blood EOS can be used as a marker to guide glucocorticoid therapy in patients with AECOPD.